Clinical Trial

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-16.
Status change: Not Yet Recruiting → Recruiting 2026-04-16
Trial Details
NCT Number NCT07082842
Lead Sponsor Sunshine Lake Pharma Co., Ltd.
Conditions Idiopathic Pulmonary Fibrosis (IPF)
Enrollment 472 participants
Start Date 2025-10-27
Primary Completion 2031-01-15 (estimated)
Study Completion 2032-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-21